Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program

Vaccine

Volumn 33, Issue 1, 2015, Pages 201-208

  Osborne, Sarah L ^a,b   Tabrizi, Sepehr N ^a,b,c,d   Brotherton, Julia M L ^c,d   Cornall, Alyssa M ^a,b,d   Wark, John D ^c,d   Wrede, C David ^b,d   Jayasinghe, Yasmin ^b,c,d   Gertig, Dorota M ^d   Pitts, Marian K ^d,e   Garland, Suzanne M ^a,b,c   Saville, M ^d   Pyman, J ^f   Tan, J ^g   Callegari, E T ^c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VCS Inc   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

^f The Royal Women's Hospital ^*  (Australia)

^g ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Cervical cancer; Facebook; Human papillomavirus; Prevalence; Surveillance; Vaginal swab

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ADVERTIZING; ARTICLE; AUSTRALIAN; DNA DETERMINATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; QUESTIONNAIRE; SELF CONCEPT; SEXUAL BEHAVIOR; SOCIAL NETWORK; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; YOUNG ADULT; ADOLESCENT; AUSTRALIA; CLASSIFICATION; GENETICS; GENOTYPING TECHNIQUE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR EPIDEMIOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; REPRODUCTIVE TRACT INFECTIONS; VAGINA; VIROLOGY;

ADOLESCENT; ADULT; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; IMMUNIZATION PROGRAMS; MOLECULAR EPIDEMIOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; QUESTIONNAIRES; REPRODUCTIVE TRACT INFECTIONS; VAGINA; VICTORIA; YOUNG ADULT;

EID: 84919445437     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.045     Document Type: Article

References (49)

1. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
2. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995, 87(11):796-802.
3. De Sanjose S., Quint W.G.V., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
4. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006, 110:525-541.
5. Bruni L., Diaz M., Castellsagué M., Ferrer E., Bosch F.X., de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202(12):1789-1799.
6. Moscicki A.B., Schiffman M., Kjaer S., Villa L.L. Updating the natural history of HPV and anogenital cancer. Vaccine 2006, 24(Suppl. 3):S42-S51.
7. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] 2014, International Agency for Research on Cancer, Lyon, France, [cited 29 May 2014]; available from: http://globocan.iarc.fr/.
8. Cervical screening in Australia 2010-2011, in Cancer Series 2013, Australian Institute of Health and Welfare, Australian Institute of Health and Welfare, Canberra.
9. Gertig D.M., Brotherton J.M.L., Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8(2):171-178.
10. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005, 32(Suppl.):1-6.
11. Tabrizi S.N., Brotherton J.M.L., Kaldor J.M., Skinner S.R., Cummins E., Liu B., et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206(11):1645-1651.
12. Gertig D.M., Brotherton J.M., Budd A.C., Drennan K., Chappell G., Saville A.M. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013, 11(1):227.
13. Crowe E., Pandeya N., Brotherton J., Dobson A., Kisely S., Lambert S., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. Brit Med J 2014, 348:g1458.
14. Ali H., Donovan B., Wand H., Read T., Regan D., Grulich A., et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. Brit Med J 2013, 346:f2032.
15. Young E., Tabrizi S., Brotherton J., Wark J., Payman J., Saville M., et al. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer 2013, 13(1):296.
16. Fenner Y., Garland S.M., Moore E.E., Jayasinghe Y., Fletcher A., Tabrizi S.N., et al. Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res 2012, 14(1):1-14.
17. Tabrizi S., Chen S., Cohenford M., Lentrichia B., Coffman E., Shultz T., et al. Evaluation of real time polymerase chain reaction assays for confirmation of Neisseria gonorrhoeae in clinical samples tested positive in the Roche Cobas Amplicor assay. Sex Transm Infect 2004, 80(1):68-71.
18. Gravitt P., Peyton C., Alessi T., Wheeler C., Coutlee F., Hildesheim A., et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38(1):357-361.
19. Layton-Henry J., Scurry J., Planner R., Allen D., Sykes P., Garland S., et al. Cervical adenoid basal carcinoma, five cases and literature review. Int J Gynecol Cancer 1996, 6(3):193-199.
20. Resnick R.M., Cornelissen M.T., Wright D.K., Eichinger G.H., Fox H.S., ter Schegget J., et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990, 82(18):1477-1484.
21. Stevens M.P., Garland S.M., Tabrizi S.N. Validation of an automated detection platform for use with the Roche Linear Array human papillomavirus genotyping test. J Clin Microbiol 2008, 46(11):3813-3816.
22. Stevens M.P., Garland S.M., Tabrizi S.N. Human papillomavirus genotyping using a modified linear array detection protocol. J Virol Methods 2006, 135(1):124-126.
23. Tabrizi S.N., Stevens M., Chen S., Rudland E., Kornegay J.R., Garland S.M. Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus. Am J Clin Pathol 2005, 123(6):896-899.
24. ®480 system. J Virol Methods 2008, 147(2):290-296.
25. National Health and Medical Research Council Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities 2005, [cited 7 July 2014]; available from: http://www.nhmrc.gov.au/guidelines/publications/wh39.
26. Australian Bureau of Statistics Table Builder Basic: 2011 Census of Population and Housing (Cat no. 20720) 2011, [cited August 2013]; available from: http://www.abs.gov.au/websitedbs/censushome.nsf/home/tablebuilder.
27. Australian Bureau of Statistics 2033.0.55.001 - Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia 2011, [cited 7 July 2014]; available from: http://www.abs.gov.au/ausstats/abs@.nsf/DetailsPage/2033.0.55.0012011.
28. Rissel C.E., Richters J., Grulich A.E., Visser R.O., Smith A. Sex in Australia: first experiences of vaginal intercourse and oral sex among a representative sample of adults. Aust N Z J Public Health 2003, 27(2):131-137.
29. Garland S.M., Brotherton J.M.L., Condon J.R., McIntyre P.B., Stevens M.P., Smith D.W., et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011, 9(104.).
30. Howell-Jones R., de Silva N., Akpan M., Oakeshott P., Carder C., Coupland L., et al. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 2012, 30(26):3867-3875.
31. Kjær S.K., Munk C., Junge J., Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?. Cancer Causes Control 2014, 25(2):179-189.
32. Kjaer S.K., Breugelmans G., Munk C., Junge J., Watson M., Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008, 123(8):1864-1870.
33. Wright T.C., Denny L., Kuhn L., Pollack A., Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. J Am Med Assoc 2000, 283(1):81-86.
34. Sellors J.W., Lorincz A.T., Mahony J.B., Mielzynska I., Lytwyn A., Roth P., et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Can Med Assoc J 2000, 163(5):513-518.
35. Winer R., Feng Q., Hughes J., Yu M., Kiviat N., O'Reilly S., et al. Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis 2007, 34(6):371-377.
36. Bhatla N., Dar L., Patro A.R., Kumar P., Kriplani A., Gulati A., et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?. Cancer Epidemiol 2009, 33(6):446-450.
37. Gravitt P., Belinson J., Salmeron J., Shah K. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer 2011, 129(3):517-527.
38. Dzuba I.G., Díaz E.Y., Allen B., Leonard Y.F., Lazcano Ponce E.C., Shah K.V., et al. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Women Health Gender Based Med 2002, 11(3):265-275.
39. Arbyn M., Verdoodt F., Snijders P.J., Verhoef V.M., Suonio E., Dillner L., et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014, 15(2):172-183.
40. Garland S.M., Tabrizi S.N. Diagnosis of sexually transmitted infections (STI) using self-collected non-invasive specimens. Sex Health 2004, 1(2):121-126.
41. Kahn J.A., Brown D.R., Ding L., Widdice L.E., Shew M.L., Glynn S., et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130(2):e249-e256.
42. Markowitz L., Hariri S., Lin C., Dunne E., Steinau M., McQuillan G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, 208(3):385-393.
43. Brown W.J., Dobson A.J., Bryson L., Byles J.E. Women's Health Australia: on the progress of the main cohort studies. J Women Health Gender Based Med 1999, 8(5):681-688.
44. Brotherton J.M., Liu B., Donovan B., Kaldor J.M., Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 2014, 32(5):592-597.
45. Burk R.D., Ho G.Y.F., Beardsley L., Lempa M., Peters M., Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996, 174(4):679-689.
46. Fairley C.K., Chen S., Ugoni A., Tabrizi S.N., Forbes A., Garland S.M. Human papillomavirus infection and its relationship to recent and distant sexual partners. Obstet Gynecol 1994, 84(5):755-759.
47. Read T.R.H., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547.
48. Department of Health Victoria Australia National Cervical Screening Program Renewal: Evidence Review 2013, [cited 17 September 2014]; available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/ncsp-renewal#consultations.
49. ®, [cited 15 September 2014]; available from: http://about.sensis.com.au/IgnitionSuite/uploads/docs/Yellow-Social-Media-Report-2014.pdf.